Thomas G Wiggans - Net Worth and Insider Trading
Thomas G Wiggans Net Worth
The estimated net worth of Thomas G Wiggans is at least $5 Million dollars as of 2024-11-28. Thomas G Wiggans is the CEO & Chairman of the Board of Dermira Inc and owns about 256,925 shares of Dermira Inc (DERM) stock worth over $5 Million. Thomas G Wiggans is the Director of Jasper Therapeutics Inc and owns about 5,000 shares of Jasper Therapeutics Inc (JSPR) stock worth over $116,200. Thomas G Wiggans is also the CEO of Pardes Biosciences Inc and owns about 50,000 shares of Pardes Biosciences Inc (PRDS) stock worth over $108,000. Details can be seen in Thomas G Wiggans's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas G Wiggans has not made any transactions after 2023-11-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Thomas G Wiggans
Thomas G Wiggans Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas G Wiggans owns 7 companies in total, including Forma Therapeutics Holdings Inc (FMTX) , Annexon Inc (ANNX) , and Dermira Inc (DERM) among others .
Click here to see the complete history of Thomas G Wiggans’s form 4 insider trades.
Insider Ownership Summary of Thomas G Wiggans
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| FMTX | Forma Therapeutics Holdings Inc | 2020-09-07 | director |
| ANNX | Annexon Inc | 2020-07-23 | director |
| DERM | Dermira Inc | 2020-02-20 | director & CEO & Chairman of the Board |
 | | 2008-06-04 | director |
| | 2022-01-25 | director |
| | 2022-12-05 | director & Chief Executive Officer |
| | 2023-11-28 | director |
Thomas G Wiggans Latest Holdings Summary
Thomas G Wiggans currently owns a total of 3 stocks. Among these stocks, Thomas G Wiggans owns 256,925 shares of Dermira Inc (DERM) as of August 19, 2019, with a value of $5 Million and a weighting of 95.55%. Thomas G Wiggans owns 5,000 shares of Jasper Therapeutics Inc (JSPR) as of November 28, 2023, with a value of $116,200 and a weighting of 2.3%. Thomas G Wiggans also owns 50,000 shares of Pardes Biosciences Inc (PRDS) as of December 5, 2022, with a value of $108,000 and a weighting of 2.14%.
Latest Holdings of Thomas G Wiggans
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| DERM | Dermira Inc | 2019-08-19 | 256,925 | 18.75 | 4,817,344 |
| JSPR | Jasper Therapeutics Inc | 2023-11-28 | 5,000 | 23.24 | 116,200 |
| PRDS | Pardes Biosciences Inc | 2022-12-05 | 50,000 | 2.16 | 108,000 |
Holding Weightings of Thomas G Wiggans
Thomas G Wiggans Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas G Wiggans has made a total of 0 transactions in Dermira Inc (DERM) over the past 5 years. The most-recent trade in Dermira Inc is the acquisition of 23,419 shares on August 19, 2019, which cost Thomas G Wiggans around $199,998.
According to the SEC Form 4 filings, Thomas G Wiggans has made a total of 3 transactions in Jasper Therapeutics Inc (JSPR) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Jasper Therapeutics Inc is the acquisition of 1,000 shares on November 28, 2023, which cost Thomas G Wiggans around $6,500.
According to the SEC Form 4 filings, Thomas G Wiggans has made a total of 2 transactions in Pardes Biosciences Inc (PRDS) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Pardes Biosciences Inc is the acquisition of 12,500 shares on December 5, 2022, which cost Thomas G Wiggans around $13,625.
Insider Trading History of Thomas G Wiggans
- 1
Thomas G Wiggans Trading Performance
GuruFocus tracks the stock performance after each of Thomas G Wiggans's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas G Wiggans is 73.92%. GuruFocus also compares Thomas G Wiggans's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas G Wiggans within 3 months outperforms 8 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Thomas G Wiggans's insider trading performs compared to the benchmark.
Performance of Thomas G Wiggans
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 12.65 | | | | | |
| Relative Return to S&P 500(%) | 10.88 | | | | | |
Thomas G Wiggans Ownership Network
Thomas G Wiggans Owned Company Details
What does Forma Therapeutics Holdings Inc do?
Who are the key executives at Forma Therapeutics Holdings Inc?
Thomas G Wiggans is the director of Forma Therapeutics Holdings Inc. Other key executives at Forma Therapeutics Holdings Inc include EVP & Research & Development Agustin Melian , SVP & Chief Scientific Officer David N Cook , and SVP & Chief Financial Officer Todd Shegog .
Forma Therapeutics Holdings Inc (FMTX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Forma Therapeutics Holdings Inc (FMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Forma Therapeutics Holdings Inc (FMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Forma Therapeutics Holdings Inc (FMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Forma Therapeutics Holdings Inc Insider Transactions
Thomas G Wiggans Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas G Wiggans. Currently GuruFocus does not have mailing address information for Thomas G Wiggans.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
